Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

Journal of Clinical Oncology

Volumn 24, Issue 22, 2006, Pages 3555-3561

  Kulke, Matthew H ^a   Bergsland, Emily K ^a   Ryan, David P ^a   Enzinger, Peter C ^a   Lynch, Thomas J ^a   Zhu, Andrew X ^a   Meyerhardt, Jeffrey A ^a   Heymach, John V ^a   Fogler, William E ^a   Sidor, Carolyn ^a   Michelini, Ann ^a   Kinsella, Kate ^a   Venook, Alan P ^a   Fuchs, Charles S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; RECOMBINANT HUMAN ENDOSTATIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CARCINOMA; DISEASE FREE SURVIVAL; DRUG SELF ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; ENDOSTATINS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SELF ADMINISTRATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33747072903     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6762     Document Type: Article

References (25)

1. O'Reilly M, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
2. Zatterstrom U, Felbor U, Fukai N, et al: Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 25:97-101, 2000
3. Perletti C, Concari P, Giardini R, et al: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60:1793-1796, 2000
4. Bergers G, Javaherian K, Lo K, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
5. Boehm T, Folkman J, Browder T, et al: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
6. Herbst R, Hess K, Tran H, et al: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 2002
7. Eder J, Supko J, Clark J, et al: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772-3784, 2002
8. Thomas J, Arzoomanian R, Albierti D, et al: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223-231, 2003
9. Kisker O, Becker C, Prox D, et al: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61:7669-7674, 2001
10. Hansma A, Broxterman H, vanderHorst I, et al: Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: A phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 16:1695-1701, 2005
11. Terris B, Scoazec J, Rubbia L: Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 32:133-138, 1998
12. Celik I, Surucu O, Dietz C, et al: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-11050, 2005
13. Olsson AK, Johansson I, Akerud H, et al: The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res 64:9012-9017, 2004
14. Wickstrom SA, Alitalo K, Keski-Oja J: Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62: 5580-5589, 2002
15. Wickstrom SA, Veikkola T, Rehn M, et al: Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res 61:6511-6516, 2001
16. Sudhakar A, Sugimoto H, Yang C, et al: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 100:4766-4771, 2003
17. Abdollahi A, Hlatky L, Huber PE: Endostatin: The logic of antiangiogenic therapy. Drug Resist Updat 8:59-74, 2005
18. Shaheen R, Davis D, Liu W, et al: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412-5416, 1999
19. Kulke M, Lenz H, Meropol N, et al: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS). J Clin Oncol 23:310s, 2005 (suppl; abstr 4008)
20. Yao J, Ng C, Hoff P, et al: Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 23:309s, 2005 (suppl; abstr 4007)
21. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005
22. Engstrom P, Lavin P, Moertel C, et al: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255-1259, 1984
23. Kouvaraki M, Ajani J, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
24. Ramanathan RK, Cnaan A, Hahn RG, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group E6282. Ann Oncol 12:1139-1143, 2001
25. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006